Conditionally replicating adenoviruses (CRAds) represent a novel approach for the treatment of cancers resistant to conventional therapies. The efficacy of CRAds might be further improved by using chemotherapeutic agents in a multimodal antitumor approach. We have evaluated the use of Ad5/3-D24, a serotype 3 receptor targeted Rb/p16 pathway selective CRAd, in combination with gemcitabine against human ovarian adenocarcinoma. The combination of these agents showed synergistic cell killing in vitro compared to single treatments. However, the effect was dependent on dose and sequencing of the agents. Our results also indicate that gemcitabine reduces the initial rate of Ad5/3-D24 replication without affecting the total amount of virus produced. Possible reasons for synergy between Ad5/3-D24 and gemcitabine include the chemosensitizing activity of E1A and/or altered replication kinetics. In an orthotopic murine model of peritoneally disseminated ovarian cancer, the combination increased the survival of mice over either agent alone, and almost 60% of treated mice were cured. Sequencing of the agents was critical for toxicity versus efficacy. Mice remained free from intraperitoneal disease, but some succumbed to treatment-related hepatic or bone marrow toxicity. This suggests that improved efficacy may uncover treatment-related toxicity, which needs to be monitored closely in clinical trials.
Introduction
Ovarian cancer is the leading cause of death from gynecologic malignancies and long-term disease-free survival of patients with metastatic disease is less than 30%. 1 Therefore, novel approaches such as targeted therapies are needed. Adenoviral cancer gene therapy can be used for killing cancer cells resistant to more traditional modalities. 2 Most adenoviral gene therapy vectors are based on serotype 5 (Ad5), which binds to the coxsackie-adenovirus receptor (CAR). Unfortunately, expression of CAR is frequently downregulated in many types of advanced cancers including ovarian cancer, 3 and may be a general phenomenon related to carcinogenesis. This could be related to the putative role of CAR in adhesion and concomitant tumor suppressing activity. Substituting the knob domain of Ad5 with the corresponding domain of serotype 3 (Ad3) allows binding and entry through the Ad3 receptor, which is expressed to high degree on ovarian cancer cells. 4 Thus, the 5/3 chimera approach is currently the 'best available' adenovirus targeting approach for ovarian cancer. 5, 6 Conditionally replicating adenoviruses (CRAds) are a potent approach for overcoming ineffective tumor penetration, which is another obstacle that has hindered clinical efficacy. 7 CRAds take advantage of tumorspecific changes that allow preferential virus replication in cancer cells. Replication causes oncolytic death of the cell, resulting in the subsequent release of the virus progeny for penetration of tumor masses.
These features were combined in Ad5/3-D24, a serotype 3 receptor targeted CRAd containing a 24 bp deletion in E1A gene. Thus, the E1A protein is unable to bind the retinoblastoma (Rb) protein for induction of viral replication in noncycling normal cells. 8 Therefore, the virus replicates selectively in cells deficient in the Rb/p16 pathway, including most cancer cells. 9 We have previously demonstrated that this agent and related variants deliver a powerful antitumor effect to ovarian cancer cells in vitro, to clinical ovarian cancer specimens, and in orthotopic models of ovarian cancer. 6, [10] [11] [12] Nevertheless, when tested in a highly sensitive in vivo imaging assay, evidence is emerging that tumors may be able to gain resistance even to this highly potent treatment. 12 This is compounded by clinical data suggesting the need for improving the potency of early generation CRAds. 7 The efficacy of oncolytic viruses might be further improved when they are used in combination with conventional therapies in a multimodal antitumor approach. In this study, we have evaluated the use of Ad5/ 3-D24 in combination with deoxycytidine analogue gemcitabine, a treatment option for taxane/platinum-resistant ovarian cancer. 13, 14 Gemcitabine has been used in combination with an oncolytic virus in a phase I-II pancreatic cancer clinical trial. 15 Therefore, it is of interest to evaluate the effect of the sequence of the treatments on potency and toxicity.
Results
Combination of Ad5/3-D24 and gemcitabine shows synergy on ovarian cancer cells in vitro
In order to determine the potential interaction between Ad5/3-D24 and gemcitabine in vitro, the cell killing effect of the combination treatment was compared to single treatments on established ovarian adenocarcinoma cell lines SKOV3.ip1 and Hey. Gemcitabine concentrations used in combination treatment were chosen based on dose-response curves for drug alone (Figures 1a and 2a) . In combination studies, cells were either treated with variable concentrations of virus, gemcitabine or both, and the cell viability was measured with MTS assay. Ad5/3luc1 was used as a replication-deficient control and it did not cause oncolysis or potentiation of gemcitabine (Figures 1b and 2b) .
Infection of SKOV3.ip1 cells at 10 VP/cell (viral particles) resulted 95% survival whereas 0.2 mg/ml gemcitabine showed 62% survival (Figure 1c) . However, when Ad5/3-D24 and gemcitabine were administered simultaneously at these concentrations, cell survival decreased to 32%. To evaluate whether the sequencing of the agents had an effect on cytotoxicity, cells were treated with gemcitabine 24 h before or 24 h after viral infection. When virus was given first, gemcitabine seemed to have little effect (Figure 1d ). Further, when gemcitabine was administered first, oncolysis caused by Gemcitabine and Ad5/3-D24 for ovarian cancer M Raki et al the virus was reduced (Figure 1e ). With Hey cells, infection at 1 VP/cell 24 h after administration of 0.2 mg/ ml gemcitabine resulted 42% cell survival whereas the survival for single agents was 100% for Ad5/3-D24 and 62% for gemcitabine (Figure 2e ). The combination seemed to be useful also when virus and gemcitabine were given simultaneously (Figure 2c ) or virus 24 h before (Figure 2d) .
Variability in the cell survival curves when treated with gemcitabine only is affected by the duration in gemcitabine exposure (3 days in Figures 1d, 2d and 4 days in other combinations). The same is true for virusonly treated cells (virus exposure 3 days in Figures 1e, 2e and 4 days in others). MTS assay measures mitochondrial activity, and therefore a slight increase was seen when the energy expenditure of cells increased due to transgene expression 10 ( Figures 1b and 2b ). Formal statistical analysis resulted in significant synergy (P ¼ 0.003) for SKOV3.ip1 cells for the simultaneous treatment group. However, this was not seen when virus was given before or after gemcitabine (P40.2). With regard to Hey cells, viral infection 24 h after gemcitabine gave synergy at a dose 0.2 mg/ml, but when the other doses were taken into the analysis, significant overall synergy was not seen (P40.1). This was also the case when cells were infected simultaneously or before gemcitabine treatment (P40.2).
Gemcitabine decreases the initial rate but not total yield of Ad5/3-D24 replication
To evaluate the effect of gemcitabine on viral replication, SKOV3.ip1 cells were infected with 10 VP/ml Ad5/3-D24 alone or in combination with 0.2 mg/ml gemcitabine and the amount of virus at different time points was determined by plaque assay. The number of infectious particles increased more rapidly after infection with Ad5/3-D24 alone in comparison with the combination treatment ( Figure 3a) . The difference was more than 1000-fold 24 h after infection and approximately 100-fold after 48 and 72 h. However, a plateau was reached for Ad5/3-D24 already after 48 h whereas viral replication was still increasing in cells treated with Ad5/3-D24 and gemcitabine. The total amount of virus production was The treatment showed synergy at a dose 0.2 mg/ml, but when the other doses were taken into the analysis, the difference was not statistically significant (P ¼ 0.143).
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Antitumor efficacy of combination treatment in an orthotopic murine model of perintoneally disseminated ovarian cancer
The antitumor efficacy of combination of Ad5/3-D24 and gemcitabine was evaluated in an orthotopic murine model of ovarian cancer. The mice were treated with a single injection of 3 Â 10 7 VP Ad5/3-D24 and 80 mg/kg gemcitabine was given every third day three times either alone, simultaneously, 24 h before, or 24 h after viral infection. Mice were followed for survival and livers were collected and processed for histopathological analysis.
The median survival of untreated mice was 30 days, and all were dead by day 34 (Figure 4) . Gemcitabine increased the median survival to 39 days (Po0.0001), but all mice died by day 53. Mice in these groups died due to disease progression (Table 1 ). In groups receiving the combination regimen (groups 4-6), a number of early deaths were seen. These were probably due to liver toxicity, manifested as either centrilobular or total necrosis of the liver (Figure 5a-f) . In hematoxylin-eosin staining, inclusion bodies were not seen. Interestingly, in one mouse treated with Ad5/3-D24+gemcitabine (virus 24 h before), we also saw evidence of hepatic extramedullary hematopoiesis (erythrocyte and myeloid precursor cells, Figure 5e ). One possible reason for this finding is bone marrow damage. 16 Nevertheless, simultaneous administration of Ad5/3-D24+gemcitabine improved the survival of mice in comparison with no treatment (Po0.0001) or gemcitabine alone (P ¼ 0.0084). While the median survival of mice treated with Ad5/3-D24 was 89 days (Po0.0001 versus no treatment, Po0.0001 versus gemcitabine), the median survival was not reached for Ad5/3-D24+gemci-tabine (virus 24 h after) as 60% of the mice were alive at the end of the experiment on day 130 (P ¼ 0.0003 versus no treatment, P ¼ 0.0002 versus gemcitabine). None of the mice treated with virus alone or in combination with gemcitabine died due to intraperitoneal relapse. Instead, mice died due to toxicity of the treatment or were killed because of subcutaneous tumors at the injection site.
Discussion
Oncolytic viruses such as CRAds have demonstrated tremendous efficacy in preclinical model systems featur- Figure 3 Effect of gemcitabine on Ad5/3-D24 replication. SKOV3.ip1 cells were infected with 10 VP/ml Ad5/3-D24 alone or in combination with 0.2 mg/ml gemcitabine (a) simultaneously or (b) 24 h after exposure to gemcitabine and the amount of virus was determined by plaque assay. Assays were performed in duplicate and data are represented as means7s.d. of the number of plaques counted from four wells. Gemcitabine decreased the initial rate of Ad5/3-D24 replication but the total virus production was similar 96 h after infection. Cell viability was retained for the duration of the experiment. Figure 4 The antitumor efficacy of combination treatment in an animal model of peritoneally disseminated ovarian cancer. SKOV3.ip1 cells were injected i.p. into SCID mice and carcinomatosis was allowed to develop. The mice received single injection of 3 Â 10 7 VP Ad5/3-D24, three doses of 80 mg/kg gemcitabine or a combination of both at different schedules. The median survival was not reached for Ad5/3-D24+gemcitabine (virus 24 h after) as 60% of mice were still alive on day 130.
Gemcitabine and Ad5/3-D24 for ovarian cancer M Raki et al ing human xenograft tumors in immune-deficient mice. 17 In contrast, while the initial clinical data have been rather promising, complete responses have been rare. 18 Therefore, there is a need for improving the potency of agents tested clinically heretofore. Although it is well known in all fields of cancer research that preclinical results do not always translate into identical clinical efficacy, an important aspect with regard to CRAds could relate to the lack of an immune-competent model system. 19 Thus, despite the dramatic treatment results in mice with a small single dose of virus (Ad5/3-D24 in Figure 4 ), maximizing clinical benefits to patients might include combination regimens.
The potency of CRAds can be improved with a number of approaches, for instance: (a) retain the replicativity of wild-type adenovirus by retaining E1B55K and E3, (b) target CRAds to tumor cells and (c) combine CRAds with other therapeutic modalities. Approaches a and b are embodied in Ad5/3-D24. Oncolytic tumor killing differs mechanistically from conventional therapies and therefore additive, synergistic or antagonistic effects are possible. The toxicity profiles of the agents may be different and could result in enhanced therapeutic efficacy without increased side effects. Cross-resistance, common for chemotherapeutics, is unlikely since agents have different mechanisms of cell killing. Finally, it may be possible to use lower treatment doses and still achieve efficacy. There are several preclinical studies suggesting enhanced cell killing and antitumor activity when CRAds and chemotherapy have been combined, [20] [21] [22] [23] [24] and the safety of the approach in humans has been demonstrated. [25] [26] [27] However, the combination of a capsid-modified CRAd with gemcitabine has not been studied yet.
Gemcitabine has been used to treat solid tumors and the drug has shown therapeutic response in a variety of malignancies, including ovarian cancer. 13, 14 The drug acts through several different mechanisms that result in self-potentiation of its activity. 28 The efficacy of gemcitabine is inhibited by upregulation of nuclear factor-kB (NF-kB) survival circuits, 29 which may be relevant for the data presented here.
Several hypotheses for the mechanism of synergy between Ad5/3-D24 and gemcitabine can be put forth:
(A) Chemotherapeutic agents may increase the level of viral replication. 23 In contrast, our results suggest that gemcitabine reduces the rate of Ad5/3-D24 replication early after infection but does not affect the total yield of virus.
(B) Slower replication could be beneficial for viral spread and eventual antitumor efficacy in this aggressive model. Mathematical modelling has been used to study the effects of replication kinetics and oncolytic potency. 30 However, it is not clear how slower replication would increase antitumor efficacy, but perhaps enhanced tumor penetration and dissemination before oncolysis and The number of mice that were alive at the end of the experiment on day 130. Gemcitabine and Ad5/3-D24 for ovarian cancer M Raki et al formation of the subsequent necrotic areas (perhaps unpenetrable to virus) are involved. Further, slower replication could be advantageous with regard to toxicity, resulting in less liver damage. In contrast, slow replication could be disadvantageous when faced with a mounting immune response.
(C) Ad5/3-D24 may augment the antitumor activity of chemotherapeutics. Adenoviral E1A protein expression has been shown to sensitize hepatocellular carcinoma cells to gemcitabine. 31 Cancer cells feature constant activity of NF-kB for avoiding apoptosis in response to harmful stimuli, including chemotherapeutic agents. 29 Suppression of NF-kB activation is one mechanism for the proapoptotic action of E1A on tumor cells. 32 E1A also suppresses the expression of poly(ADP-ribose) polymerase (PARP), which plays an important role in DNA repair. 31 Interestingly, as a mechanism for gaining resistance, NF-kB and PARP are induced in cancer cells treated with gemcitabine, while E1A inhibits NF-kB and PARP, consecutively resulting in sensitization of cells to gemcitabine. 31 These aspects may also partially account for the hepatic toxicity seen here. Although human adenoviruses do not productively replicate in murine cells, E1A expression and protein production does ensue. 33 Theoretically, this could sensitize normal cells to gemcitabine-mediated damage. Although the capsid modification used here increases the tropism of the virus to tumor cells, it has little effect on the biodistribution in general and the liver transduction in particular. 5 Therefore, it will be interesting to see if other oncolytic viruses result in similar findings.
(D) It has been reported that expression of CAR can be induced with certain chemotherapeutic agents. 34 Increased receptor expression has not been shown for the Ad3 receptor, but in theory, it could play a role. Although CD46 has been suggested as a possible Ad3 receptor, 35 other reports disagree. 36 Once the receptor is identified, possible upregulation mediated by gemcitabine can be studied.
(E) Finally, each agent could work independently on different cell populations. It is possible that gemcitabine may also be able to kill tumor surrounding stromal cells of murine origin, in particular when sensitized with E1A.
In conclusion, we demonstrate synergy between gemcitabine and Ad5/3-D24 for the treatment of ovarian cancer. Antitumor efficacy was increased, but in the immunocompromized mice used here, antiviral antibodies are not formed, and liver damage was also seen. It is possible that virus replication would be more abrogated in immunocompetent systems resulting in less hepatic toxicity, while antitumor efficacy might remain, due to the relative protection from the immune system provided by the tumor environment. Importantly, 60% of mice treated with Ad5/3-D24 after gemcitabine were cured from their disease without obvious side effects. Pending clinical testing, these results could provide hope to patients with incurable ovarian cancer.
Materials and methods

Cells, viruses and chemotherapeutics
Human ovarian adenocarcinoma cell lines SKOV3.ip1 and Hey, human transformed embryonal kidney cell line 293, and human lung adenocarcinoma cell line A549 were cultured in the recommended conditions as reported. 4 Characterization and production of Ad5/3-D24 and Ad5/3luc1 have been reported previously. 4, 11 Gemcitabine (Gemzar R ) was obtained from Eli Lilly and Company (Indianapolis, IN, USA). The stock solution was prepared in 0.9% NaCl and the agent was further diluted in growth media immediately before use.
Cell viability
Ovarian adenocarcinoma cells were seeded at 1.5 Â 10 4 cells/well on 96-well plates and cultured overnight. Cells in triplicate were either infected with virus, treated with gemcitabine or with a combination of both. Viral infection 24 h before or 24 h after gemcitabine treatment was also performed. Ad5/3-D24 and Ad5/3luc1 were added at the indicated VP/cell diluted in 50 ml of growth medium containing 5% FBS. Gemcitabine was dosed in 50 ml of growth medium with 5% FBS and the drug was present during the whole experiment. Cells were incubated at 371C and cell viability was measured 4 days after infection using the CellTiter 96 AQ ueous One Solution Cell Proliferation Assay (MTS assay) (Promega, Madison, WI, USA). Prior to combination treatments, the therapeutic window of gemcitabine was determined for each cell line by incubating in the presence of increasing concentrations of the drug and performing MTS assay 3 days later.
Statistical analysis
Chou and Talalay's median-effect method 37 was used to calculate combination index (CI) values under assumption of mutually nonexclusive drug interactions using SPLUS 6.0. CI equation of o1 indicates synergism, 1 ¼ additivity, and CI41 indicates antagonism. One sample t-test was performed to determine whether the mean CI values from separate experiments at multiple effect levels were significantly different from a value of 1.0. Within-experiment standard deviations were calculated with Microsoft Excel. Survival data were plotted into a Kaplan-Meier curve and groups were compared pair-wise with log-rank test using SPSS 11.5.
Quantitation of viral replication
SKOV3.ip1 cells were seeded at 5 Â 10 5 cells/well on sixwell plates and cultured overnight. Cells were infected with 10 VP/ml Ad5/3-D24 alone or in combination with 0.2 mg/ml gemcitabine in 1 ml of growth medium with 2% FBS. After 12 h, growth medium was changed either to 3 ml of medium with 5% FBS or 3 ml of medium containing 0.2 mg/ml gemcitabine and 5% FBS. Cells and medium were harvested 24-96 h postinfection and lysed by three freeze-thaw cycles. The amount of infectious particles present in the resulting supernatants was determined by plaque assay on 293 cells. Viral infection 24 h after exposure of cells to gemcitabine was performed using the same doses and protocol as above. Time point 0 is mock infected cells, whose value was set at 1 for presentation on a log axis (no plaques were seen). Finland. Mice were injected intraperitoneally (i.p.) with 10 7 SKOV3.ip1 cells and carcinomatosis was allowed to develop. Mice were then randomized into six treatment groups (n ¼ 11-12/group): (1) growth medium i.p. on day 10, (2) 3 Â 10 7 VP Ad5/3-D24 i.p. on day 10, (3) 80 mg/kg gemcitabine i.p. on days 10, 13 and 16. (4) Ad5/3-D24 and gemcitabine simultaneously at the same doses and schedules as above, (5) Ad5/3-D24 on day 10 and gemcitabine on days 11, 14 and 17 and (6) gemcitabine on days 10, 13 and 16 and Ad5/3-D24 on day 11. This dose of gemcitabine has been demonstrated to be well within the therapeutic window in mice and therefore the respective human dose would be predicted to be well tolerated. 38 All injections were diluted into 0.5 ml. This experiment was designed based on the in vitro results and previous experience we have with these viruses and models. 11 The health of the mice was monitored daily and they were killed when there was evidence of pain or distress. Livers were collected and fixed in buffered formalin (10%), paraffin-embedded and cut into 5 mm sections. Deparaffinized specimens were stained with hematoxylin and eosin.
Intraperitoneal ovarian cancer model
